Where can I learn more about this study?
You can find more information about this study on the websites listed below. If
more information about the study results is available, it can also be found here.
> www.clinicaltrials.gov. Once you are on the website, type “NCT04256629”
into the search box and click “Search”.
> www.clinicaltrialsregister.eu. Once you are on the website, click “Home and
Search”, then type “2019-003657-28” in the search box and click “Search”.
> www.AstraZenecaClinicalTrials.com. Once you are on the website, type
“D5495C00012” into the search box, and click “Find a Study”.
Full Study Title: A Single-Centre, Randomised, Double-Blind, Placebo-
Controlled, 3-Period, Cross-Over Phase I Study to Investigate the Effect on the QTcF
Interval of a Single Dose of 2 Different Doses of Verinurad, Each in Combination
with Allopurinol 300 mg, Compared with Placebo In Healthy Volunteers.
AstraZeneca Protocol Number: D5495C00012
National Clinical Trials number: NCT04256629
EudraCT number: 2019-003657-28
AstraZeneca AB sponsored this study and has its headquarters at
151 85 Södertälje, Sweden.
The phone number for the AstraZeneca Information Center is +1-877-240-9479
and the email is information.center@astrazeneca.com.
Thank you!
Clinical study participants and their families belong to a large community of
people who take part in clinical research around the world. They help researchers
answer important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization
focused on educating and informing the public about clinical research participation. CISCRP is not
involved in recruiting participants for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_05_04
9 | Clinical Study Results